Home › Compare › PCRAF vs PM

PCRAF vs PM: Dividend Comparison 2026

PCRAF yields 7181.33% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PCRAF wins by $2129323467795842.25M in total portfolio value
10 years
PCRAF
PCRAF
● Live price
7181.33%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2129323467795842.25M
Annual income
$2,072,550,944,745,044,800,000.00
Full PCRAF calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — PCRAF vs PM

📍 PCRAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPCRAFPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PCRAF + PM cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PCRAF pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PCRAF
Annual income on $10K today (after 15% tax)
$610,412.93/yr
After 10yr DRIP, annual income (after tax)
$1,761,668,303,033,288,000,000.00/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, PCRAF beats the other by $1,761,668,303,033,288,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PCRAF + PM for your $10,000?

PCRAF: 50%PM: 50%
100% PM50/50100% PCRAF
Portfolio after 10yr
$1064661733897921.13M
Annual income
$1,036,275,472,372,522,400,000.00/yr
Blended yield
97.33%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

PCRAF
No analyst data
Altman Z
-16.9
Piotroski
0/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PCRAF buys
0
PM buys
0
No recent congressional trades found for PCRAF or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPCRAFPM
Forward yield7181.33% ✓3.48%
Annual dividend / share$2.00$5.76 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2% ✓
Portfolio after 10y$2129323467795842.25M ✓$49.6K
Annual income after 10y$2,072,550,944,745,044,800,000.00 ✓$2,492.02
Total dividends collected$2125520801706147.50M ✓$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: PCRAF vs PM ($10,000, DRIP)

YearPCRAF PortfolioPCRAF Income/yrPM PortfolioPM Income/yrGap
1← crossover$728,833$718,132.85$11,648$408.29+$717.2K → PCRAF
2$49,695,629$48,915,777.42$13,589$495.90+$49.68M → PCRAF
3$3,170,308,012$3,117,133,689.10$15,877$603.21+$3170.29M → PCRAF
4$189,238,958,407$185,846,728,834.15$18,580$734.88+$189238.94M → PCRAF
5$10,570,133,462,966$10,367,647,777,471.07$21,781$896.75+$10570133.44M → PCRAF
6$552,520,748,327,293$541,210,705,521,919.44$25,578$1,096.12+$552520748.30M → PCRAF
7$27,030,543,997,490,970$26,439,346,796,780,764.00$30,092$1,342.17+$27030543997.46M → PCRAF
8$1,237,774,696,255,956,700$1,208,852,014,178,641,400.00$35,470$1,646.46+$1237774696255.92M → PCRAF
9$53,058,432,757,754,490,000$51,734,013,832,760,615,000.00$41,892$2,023.58+$53058432757754.45M → PCRAF
10$2,129,323,467,795,842,200,000$2,072,550,944,745,044,800,000.00$49,578$2,492.02+$2129323467795842.25M → PCRAF

PCRAF vs PM: Complete Analysis 2026

PCRAF — Stock

Pucara Gold Ltd. engages in the acquisition, exploration, and evaluation of mineral properties in Peru. The company explores for gold, copper, zinc, lead, and silver deposits. Its project portfolio includes the Lourdes, Pacaska, Capricho, Guadalupe, Keyla, Paco Orco, Pucapaca, and Santo Tomas Projects located in Peru. Pucara Gold Ltd. is based in Vancouver, Canada.

Full PCRAF Calculator →

PM — Consumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this PCRAF vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PCRAF vs SCHDPCRAF vs JEPIPCRAF vs OPCRAF vs KOPCRAF vs MAINPCRAF vs MOPCRAF vs BTIPCRAF vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.